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Glucagon-like peptide 1 (GLP-1) and cholecystokinin (CCK) are gut-derived peptide hormones known 
to play important roles in the regulation of gastrointestinal motility and secretion, appetite, and food 
intake. We have previously demonstrated that both GLP-1 and CCK are produced in the endocrine 
pancreas of obese mice. Interestingly, while GLP-1 is well known to stimulate insulin secretion by 
the pancreatic β-cells, direct evidence of CCK promoting insulin release in human islets remains to be 
determined. Here, we tested whether islet-derived GLP-1 or CCK is necessary for the full stimulation of 
insulin secretion. We confirm that mouse pancreatic islets secrete GLP-1 and CCK, but only GLP-1 acts 
locally within the islet to promote insulin release ex vivo. GLP-1 is exclusively produced in approximately 
50% of α-cells in lean mouse islets and 70% of α-cells in human islets, suggesting a paracrine α to 
β-cell signaling through the β-cell GLP-1 receptor. Additionally, we provide evidence that islet CCK 
expression is regulated by glucose, but its receptor signaling is not required during glucose-stimulated 
insulin secretion (GSIS). We also see no increase in GSIS in response to CCK peptides. Importantly, all 
these findings were confirmed in islets from non-diabetic human donors. In summary, our data suggest 
no direct role for CCK in stimulating insulin secretion and highlight the critical role of intra-islet GLP-1 
signaling in the regulation of human β-cell function.
The precise control of blood glucose is dependent on the islets of Langerhans located within the pancreas. 
Pancreatic islets are complex structures consisting of several types of cells, including insulin-producing β-cells, 
glucagon-producing α-cells, and somatostatin-producing α-cells. After feeding, nutrients stimulate insulin 
release by the β-cell and the circulating hormone acts on peripheral tissues lowering blood glucose. The full stim-
ulation of insulin secretion after food intake depends on the incretin effect of gut-derived peptide hormones and 
paracrine signaling within the islet1.
We and others discovered that two classic gut hormones, glucagon-like peptide 1 (GLP-1) and cholecystokinin 
(CCK), are also produced by pancreatic islets2–5. GLP-1 is a peptide hormone mainly secreted by intestinal L-cells 
and is known to decrease blood glucose levels by enhancing β-cell insulin secretion6. CCK is a peptide hormone 
mainly secreted by intestinal I-cells and is involved in the digestion of nutrients7 and regulation of food intake8. 
The production of both GLP-1 and CCK in the islet has been associated with β-cell expansion and survival in 
response to metabolic stress5,9. While each of these gut-derived hormones can contribute to improvements in 
glucose homeostasis10,11, it is unclear whether their local production in the islet contributes to β-cell function. 
Moreover, it is unknown whether CCK stimulates insulin release in human islets. Here, we describe experiments 
with GLP-1 and CCK receptor antagonists in isolated mouse and human islets to assess β-cell function ex vivo. 
Our data demonstrate that pancreatic CCK is not required for glucose-stimulated insulin secretion (GSIS) and 
CCK peptide does not potentiate GSIS. Furthermore, we demonstrate that intra-islet GLP-1 signaling between α 
to β-cell is necessary for normal insulin secretion.
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Results
Expression of pancreatic GLP-1 in mouse and human islets. Emerging evidence supports the produc-
tion of GLP-1 in pancreatic islets3,4,12,13. Prohormone convertase 1/3 (PC1/3), the enzyme responsible for GLP-1 
cleavage from a proglucagon precursor, has been detected in rodent glucagon-producing cells, especially under 
β-cell stress conditions2,14,15. However, the number of α-cells producing GLP-1 in non-stressed conditions has gen-
erally been assumed to be relatively few. Here, we evaluate whether fully processed active GLP-1 can be detected 
in islets isolated from lean mice and non-diabetic human donors and quantify its expression patterns using an 
antibody specific for the processed and biologically active GLP-1 (7–36) amide form that does not cross-react 
with glucagon peptide3. The challenge for α-cell quantification in rodents includes the low number of α-cells 
in the islet (<10% in mouse islets). To overcome this problem, we dispersed islets into single-cells right before 
staining to maximize the number of α-cells counted in each experiment. As expected, mouse islets had fewer 
α-cells compared to humans (Fig. 1A). We detected active GLP-1 in both mouse and human islet cells (Fig. 1B). 
Quantification analysis shows that approximately 50% of glucagon-positive cells co-express GLP-1 in lean mice 
(Fig. 1C–G). Surprisingly, these bi-hormonal cells were near 70% in humans (Fig. 1C,H–K). Essentially all of the 
GLP-1 expressing cells were α-cells. The body mass index (BMI) of the donors of the human islets used ranged 
from 28.5–31.8 kg/m2 (islet preparations 5–8, Suppl. Table 1), consistent with our previous study in which islet 
GLP-1 secretion is increased in obesity4. Also, dispersed mouse islet cells had a similar expression pattern as intact 
islets (Suppl. Fig. 1), suggesting that acute islet dispersion did not affect either glucagon or GLP-1 expression. 
Together, our results suggest that GLP-1 is produced in a high percentage of α-cells, especially in human islets.
Paracrine GLP-1 signaling is necessary for GSIS. To test whether α-cell-derived GLP-1 plays an impor-
tant paracrine role in β-cell function, we first measured bioactive GLP-1 secreted into the islet media as detected 
by active GLP-1 ELISA. Human islets secreted over 10-fold more GLP-1 than mouse islets on a per islet basis 
(Fig. 2A,B), consistent with the higher number of GLP-1-positive cells observed in Fig. 1 as well as with a recent 
work comparing mouse vs. human pancreatic GLP-116. We then tested whether paracrine GLP-1 signaling is 
necessary for normal glucose-stimulated insulin secretion by performing static GSIS studies in the presence of 
exendin-(9–39) (Ex9), a specific GLP-1 receptor (GLP-1R) antagonist17. We found that Ex-9 blunted GSIS in both 
mouse and human islets (Fig. 2C). Insulin content did not change significantly across all conditions and we found 
similar GSIS results when secretion was normalized to percentage of insulin content (data not shown). These 
results demonstrate that intra-islet GLP-1 signaling is necessary for GSIS in humans.
Figure 1. GLP-1 expression in pancreatic α-cells. (A) Percentage of glucagon-positive cells, (B) GLP1-positive 
cells, and (C) glucagon cells double positive for glucagon and GLP-1. Representative images of co-localization 
of GLP-1 (7–37) (green), glucagon (red) and DAPI (blue) in mouse (D–G) and human (H–K) islet cells. Scale 
bars, 200 µm. Data are mean ± SEM of 4 islet preparations.
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CCK signaling in mouse and human islets. CCK is another peptide hormone commonly expressed in 
neuroendocrine cells in the gut, yet rodent pancreatic islets also express and secrete CCK under conditions of 
metabolic stress such as obesity and insulin resistance5,18,19. Here, we confirmed our previous findings5 that Cck 
is up-regulated in leptin-deficient obese mouse islets (ob/ob) (Fig. 3A). Since CCK has two known receptors, 
CCKAR and CCKBR20, we then tested if a specific receptor signaling pathway is more relevant in the islet or 
changed by obesity. We found that islets from either lean or obese animals had relatively low mRNA levels of both 
Cckar and Cckbr (Fig. 3A). In human islets, we confirmed the presence of CCK and CCKAR4 and provide new 
evidence that CCKBR is also present (Fig. 3A). Unlike in mice, we found no significant correlation between CCK, 
CCKAR, or CCKBR expression and donor BMI among donors without diabetes (Suppl. Fig. 2).
Since insulin resistance and hyperglycemia are common correlates of obesity, we hypothesized that glucose 
may be regulating CCK expression in the islet. We have previously shown that the ability of cyclic AMP (cAMP) 
to stimulate CCK expression in INS-1 cells was enhanced in high glucose conditions4. We incubated islets in high 
concentrations of glucose and determined CCK expression by quantitative real-time PCR (qPCR). After 24 h expo-
sure to high glucose, there was an approximately 7-fold increase in Cck mRNA levels in lean mouse islets (Fig. 3B). 
Interestingly, we found a similar stimulatory effect of glucose on CCK expression in response to glucose in isolated 
islets from two non-diabetic human donors (Fig. 3C). We saw no significant difference in CCKAR or CCKBR 
expression in response to glucose in either mouse or human islets (Fig. 3C,D). Because α-cells produce and release 
GLP-13,4,12,13 (Figs. 1 and 2A,B) and GLP-1 can stimulate the production of CCK from β-cells4, we asked whether 
the induction of Cck by glucose is dependent on paracrine GLP-1 signaling. We found that glucose increased Cck 
by approximately 6-fold in mouse islets even when GLP-1R antagonist was present during the culture (Fig. 3E). 
Our previous work found that GLP-1 increases β-cell CCK mRNA expression and CCK peptide secretion through 
cAMP/CREB signaling in INS-1 cells4. Here we show that human islets also secrete active sulfated CCK peptide 
and that this secretion is enhanced by exposure to a cell-permeable cAMP analogue (Fig. 3F). Taken together, our 
results demonstrate that the effect of glucose on islet CCK expression is not GLP-1 receptor-dependent and further 
support the role of cAMP signaling in islet/β-cell CCK secretion even in human islets.
Paracrine CCK signaling is not necessary for GSIS. Although it is not classified as an incretin hor-
mone due to a general lack of effect on in vivo insulin secretion, CCK has been proposed to regulate insulin 
secretion in isolated rat islets21. We, therefore, hypothesized that, like pancreatic GLP-1, intra-islet CCK could 
also regulate β-cell insulin secretion. To test this, we performed in vitro and ex vivo studies in mouse and human 
islets. Here, we confirmed that CCK secretion is higher from ob/ob compared to lean mouse islets5 and show 
that non-diabetic human islets secrete small amounts of active, sulfated CCK peptide (Fig. 4A). Importantly, we 
used a radioimmunoassay specific for sulfated CCK peptides with no cross-reactivity to gastrin peptide (Alpco, 
based on assay developed in22). Since CCK has been proposed to stimulate insulin release in rodents21, we asked 
whether intra-islet CCK signaling is necessary for β-cell function. To answer this, we performed ex vivo GSIS in 
the presence of proglumide, a non-selective CCK receptor antagonist23. In contrast to Ex9 (Fig. 2C), we found that 
proglumide did not affect GSIS (Fig. 4B). This finding was consistent even in the islets from obese mice, which 
had both higher CCK and insulin release (Fig. 4A,B). Similarly, proglumide did not inhibit GSIS in human islets 
(Fig. 4B). Therefore, these results demonstrate that paracrine CCK signaling is not necessary for β-cell glucose 
stimulated insulin secretion.
CCK does not regulate GSIS. The small amount of CCK released from the islet could be a reason for the 
lack of effect on β-cell function in a paracrine manner. However, in humans, the ability of CCK to stimulate 
insulin secretion is controversial24–26 and has not been previously tested in isolated islets. Therefore, we tested if 
Figure 2. Paracrine GLP-1 signaling is required for ex vivo GSIS. GLP-1 (7–36 amide) and (7–37) released 
during the culture of mouse (A) and human (B) islets in RPMI containing 11 mM (A) and 8 mM glucose (B), 
respectively. (C) Insulin secreted from batches of 5 islets after 1 h incubation at 3 or 15 mM glucose (3 G and 
15 G, respectively) or 15 G in the presence of 1 µM exendin-(9–39) (Ex9), a specific GLP-1R antagonist. Insulin 
values were normalized to the islet DNA content from each batch (total of 9–12 batches/condition). Significance 
was tested by two-way ANOVA and Bonferroni’s post-hoc test. Data are mean ± SEM of 3–4 islet preparations. 
*P < 0.05.
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pharmacologic levels of CCK could directly potentiate insulin secretion ex vivo. We performed static GSIS studies 
in the presence of 100 nM21 of sulfated (pGlu-Gln)-CCK-8, a stable CCK analog peptide27, at either low or high 
glucose. Contrary to our expectations, we found that exogenous CCK did not affect GSIS in human or mouse 
Figure 3. CCK gene expression is regulated by glucose. (A) mRNA levels of cholecystokinin (Cck), and CCK 
receptors (Cckar and Cckbr) in islets isolated from lean or obese mice. (B) CCK, CCKAR, and CCKBR in isolated 
human islets. mRNA levels in lean mouse (C) and human islets (D) after 24 h culture in high glucose (25 mM 
glucose). (E) Cck in lean mouse islets after 24 h culture in high glucose in presence of 200 nM exendin-(9–39) 
(HG + Ex9). (F) Sulfated cholecystokinin (CCK) released into the media during culture of human islets 
with 10 µM 8-CPT-cAMP. Significance was tested by Student’s t-test (B,C,F) and one-way ANOVA follow by 
Bonferroni’s post-hoc test (D). Data are mean ± SEM (n = 5 for mouse and n = 2 for human). *P < 0.05.
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islets (Fig. 5). We then tried a high concentration of (pGlu-Gln)-CCK-8, 1 µM. In a recent publication, Khan, 
et al. found that only at this 1 µM concentration of (pGlu-Gln)-CCK-8 was there a modest increase in GSIS in 
isolated mouse islets28. However, we were unable to replicate these findings in mouse islets and even at this high 
concentration (pGlu-Gln)-CCK-8 did not augment GSIS (Fig. 5C). As CCKR signaling can stimulate increases 
in intracellular calcium (Ca2+) in rat islets and other cell types21,29,30 and this could be the trigger for insulin 
secretion in a β-cell, we measured cytosolic Ca2+ in β-cells of isolated mouse islets before and after the addition of 
1 µM CCK. We did not see a rapid or significant increase in intracellular Ca2+ levels in response to CCK as would 
be expected to trigger insulin secretion (Fig. 5D). Importantly, all cells increased cytosolic Ca2+ after 1 µM ace-
tylcholine (ACh), assuring that β-cell Ca2+ signaling was not impaired31. We repeated our GSIS assay in a 2 hour 
static incubation in INS-1 cells and again did not see any augmentation of GSIS with 100 nM (pGlu-Gln)-CCK-8 
treatment (Suppl. Fig. 3). To ensure that this was not an effect of the modified (pGlu-Gln)-CCK-8 peptide, we 
repeated the assay with sulfated CCK-8, a native CCK peptide27, and still did not stimulate insulin secretion in 
β-cells whether normalized to insulin content or DNA content (Suppl. Fig. 3). Collectively, our results show no 
evidence that CCK directly promotes insulin secretion.
Discussion
The gut peptide hormone GLP-1 has been widely studied for its beneficial effects on β-cell insulin secretion and 
blood glucose control6. CCK has also been documented to stimulate insulin release in rodents21,28 and humans26. 
Here, we show that both hormones are secreted from mouse and human pancreatic islets but only GLP-1 acts 
locally within the islet to promote insulin release. Additionally, we demonstrate that while CCK expression is 
regulated by glucose, its receptor signaling is dispensable for GSIS. Our data highlight the critical role of paracrine 
GLP-1 within the islet to maintain glucose homeostasis. We find that CCK is expressed and dynamically regulated 
in human islets, but its paracrine role in islet function remains unknown.
GLP-1 produced by L cells in the gut is classically thought to act as an endocrine hormone on β-cells through 
the circulation. We and others have shown that islet GLP-1 is increased during conditions of islet-stress2,4,14,15,32, 
likely through increased pro-glucagon transcription and PC1/3 expression9. PC1/3 is highly expressed in β-cells 
because it is required for pro-insulin processing33. However, previous studies have shown that pancreatic α-cells 
contain the cellular machinery necessary to synthesize and secrete GLP-1, including PC1/32,3,13 (and online data-
set from Benner et al.34), suggesting that GLP-1 could also be produced in non-stressed islets. Based on these data, 
we9 and others12,15 have hypothesized that α-cell-derived GLP-1 acts on β-cell GLP-1R9. Here, GLP-1R antagonist 
markedly inhibited GSIS in islets from lean mice as well as from non-diabetic human donors, demonstrating that 
GLP-1 paracrine signaling pathways are already active in non-stressed β-cells (Fig. 2B). This suggests that there 
is a sufficient amount of GLP-1 present locally within the islet to activate its receptor on the neighboring β-cell. 
Indeed, we detected active GLP-1 being synthesized and released from both mouse and human islets, with an 
even greater amount in human islets than previously appreciated (Figs. 1 and 2A).
Previous studies have similarly suggested a paracrine signaling between α and β-cells where α-cell prod-
ucts directly regulate β-cell function35. A recent study showed that β-cell function depends on a local intra-islet 
glucagon signaling in mouse islets36. Furthermore, it has been shown that β-cell GLP-1R is necessary for glu-
cose homeostasis and is dependent on Gcg peptides being produced in the islet10. Our study supports these 
findings and provides new evidence of α-cell-derived GLP-1 acting within the islet to promote β-cell function. 
Interestingly, glucagon has been reported as a relative low-potency agonist of GLP-1 receptor37, including in 
primary rodent β-cells36,38. Although our present data show that human islets produce and release much more 
Figure 4. Paracrine CCK signaling is not required for ex vivo GSIS. (A) Sulfated cholecystokinin (CCK) 
released into the media during islet culture. (B) Insulin secreted from batches of 5 islets after 1 h incubation at 
3 or 15 mM glucose (3 G and 15 G, respectively) or 15 G in the presence of 1 µM proglumide, a non-selective 
CCK receptor antagonist. Insulin values were normalized to the islet DNA content from each batch (total of 
9–21 batches/condition). Significance was tested by two-way ANOVA and Bonferroni’s post-hoc test. Data are 
mean ± SEM of 3–7 islet. preparations.
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GLP-1 in comparison to lean mouse, we cannot account for the possibility that other α-cell-derived peptides (i.e. 
glucagon) are also acting on β-cell GLP-1R36,38. Nevertheless, there is a limited understanding of this local signa-
ling in vivo and more research is needed to confirm the relative role of α-to-β-cell crosstalk in regulating glucose 
homeostasis in humans.
In the present study, we also addressed whether pancreatic CCK might influence islet function in a paracrine 
manner. Since CCK has been shown to stimulate insulin secretion in rat islets21 and humans26, we predicted that 
islet-derived CCK would affect β-cell insulin secretion. However, blocking CCK receptors did not decrease GSIS, 
suggesting that intra-islet CCK does not potentiate insulin release via its receptors. Moreover, there was no insu-
linotropic action of CCK analog peptide in isolated islets. This result was a bit surprising, however most of the 
studies demonstrating a direct effect of CCK on GSIS were performed in rat islets21,39. Several other in vivo stud-
ies in mice and humans failed to demonstrate enhanced GSIS with CCK administration25,27,40. While the exact 
experimental conditions (CCK concentration, incubation methods) differ in much of the literature, we directly 
tested conditions previously used to demonstrate that CCK peptide at 1 μM enhanced GSIS in mouse islets and 
could not replicate those findings (Fig. 5C)28. Interestingly, our live-cell imaging results suggest that CCK peptide 
does not activate robust increases in intracellular Ca2+ in mouse β-cells as it does in pancreatic acinar cells30 or 
vagal afferent neurons29 and in rat islet21, and this lack of an effect on calcium influx may explain the inability to 
stimulate insulin secretion. In humans, both CCK receptor antagonists and CCK peptides did not affect insulin 
release ex vivo (Figs. 4B and 5B) or in vivo41,42, suggesting that CCK does not act as physiological incretin hor-
mone. However, as CCK receptors are also expressed in other tissues, the peptide may be involved in the neural 
regulation of insulin secretion43, reduction of hepatic glucose production11 and control of food intake27. CCK 
may also play a role in other regulated insulin secretion, such as amino acid-stimulated insulin secretion44 or the 
enhancement of GSIS by GLP-145. These beneficial effects, along with the impact of CCK on β-cell survival4,5,46, 
still make CCK a strong therapeutic candidate with the potential to treat obesity and type 2 diabetes47.
With increasing data indicate that classical gut hormones are produced locally in the islet4,13,48,49, many ques-
tions remain to be answered. For example, the molecular signals that turn on GLP-1/CCK expression in islet-cells 
Figure 5. CCK does not stimulate ex vivo GSIS. Insulin secreted from (A,C) mouse and (B) human islets. 
Batches of 5 islets after 1 h incubation at 3 or 15 mM glucose (3 G and 15 G, respectively) in the presence of 
100 nM (A,B) or 1 µM (C) sulfated pGlu-Gln-CCK-8 (CCK). Insulin values were normalized to DNA content 
from each batch (total of 9–12 batches/condition). (C) Cytosolic calcium (Ca2+) levels measured in mouse islet 
β-cells at 8 mM glucose (8 G) stimulated with 1 µM sulfated pGlu-Gln-CCK-8 (CCK) and 1 µM acetylcholine 
(ACh). Significance was tested by two-way ANOVA and Bonferroni’s post-hoc test. Data are mean ± SEM of 
3–4 islet preparations.
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remain to be fully elucidated. Also, a more detailed analysis of GLP-1/CCK-expressing cells in both mouse and 
human islets is warranted given there are several species differences. Both hormones act not only locally, but 
also systemically, increasing the complexity of understanding their overall impact on glucose homeostasis and 
beta-cell mass regulation. We have previously shown that overexpressing CCK in mouse β-cells does not change 
exocrine pancreas histology, nor systemic circulation of CCK peptide, suggesting that islet-derived hormone 
likely does not contribute significantly to systemic levels46. Similarly, recent studies showed that pancreatic 
GLP-1 does not necessarily change systemic GLP-1 circulating levels in mice10,50,51. These findings enhance our 
understanding on the biology of incretins and may open new possibilities for therapeutic innervations, including 
directed therapies to activate local pathways and avoid systemic side effects.
Overall, our results point to a physiological significance of paracrine GLP-1 but not CCK signaling in pro-
moting glucose-stimulated insulin secretion in both mouse and human islets, suggesting that α to β-cell com-
munication through GLP-1 receptor signaling is critical in the control of islet function and glucose homeostasis. 
Paracrine signaling of CCK is likely more important in β-cell survival pathways than in β-cell function and may 
be dynamically regulated by hyperglycemia.
Methods
Animals, islet isolation and culture. Animal care and experimental procedures were performed with 
approval from the Institutional Animal Care and Use Committee from the University of Wisconsin (protocol 
M005210) and William S. Middleton Memorial Veterans Affairs (protocol DD0001) to meet acceptable standards 
of humane animal care. All experiments were carried out in accordance with their guidelines and regulations. All 
animals used in this study were housed in facilities with a standard light-dark cycle and fed ad libitum. Pancreatic 
mouse islets were isolated from male 12–16 week old C57BL/6J and B6.Cg-Lepob/J (ob/ob) (Jackson Laboratory, 
ME) as described previously52. Briefly, islets were isolated by collagenase digestion and Histopaque gradient 
(Sigma, #10771). Then, islets were handpicked and cultured at 37 °C and 5% CO2 in RPMI 1640 media (Thermo 
Fisher Scientific, #11875093) containing 11 mM glucose and supplemented with 5 g/l BSA fraction V (Roche, 
#107351080001), 100 units/ml penicillin and 100 μg/ml streptomycin (1% P/S) (Thermo Fisher Scientific).
Human islets. Human islets were obtained through the Integrated Islet Distribution Program (https://iidp.
coh.org/) (Suppl. Table 1). Upon arrival, islets were handpicked and then cultured in RPMI 1640 media (Thermo 
Fisher Scientific, #11879020) containing 8 mM glucose and supplemented as described above. Islets were cultured 
up to 7 days and the media was renewed every other day.
mRNA levels. Gene expression analysis was performed as previously described4,46. RNA was isolated using 
either TRIzol or the QIAGEN RNeasy mini kit according to the manufacturer’s instructions. cDNA was prepared 
using Applied Biosystems High Capacity cDNA synthesis kit, then analyzed by quantitative PCR (qPCR) using 
Power SYBR Master Mix (Life Technologies). All transcripts were normalized to β-actin. mRNA levels are shown 
as −ΔCT (CT[housing keeping] − CT[interest gene]). Fold changes were calculated relative to controls.
Islet immunohistochemistry. Islets were dispersed at 37 °C using 0.25% Trypsin-EDTA (Thermo Fisher 
Scientific, #25200056), plated on Poly-L-lysine pre-coated glass coverslips and fixed with 10% formalin. Samples 
were permeabilized, blocked (Dako, #X0909) and then incubated with rabbit anti-glucagon (Santa Cruz, 1:200 
– discontinued) and mouse anti-GLP-1 (7–36) amide (Abcam #ab26278, 1:200) antibodies. Abcam #ab26278 
anti-GLP-1 (7–36) amide antibody recognizes the amidated C-terminus of the GLP-1(7–36) peptide and shows 
no cross-reactivity with non-amidated GLP-1, GLP-2, glucagon, or GIP53. Anti-rabbit Alexa Fluor 594 (1:400) 
and anti-mouse Alexa Fluor 488 (1:400) were used as secondary antibodies. Imaging was performed using an 
EVOS FL microscope. Manual scoring of images for co-localized glucagon, GLP-1, and DAPI (Dako) was per-
formed using ImageJ (NIH) or Photoshop (Adobe) of, at least, 9 randomly chosen fields per treatment group for 
each replicate. DAPI staining was used as a nuclear marker while glucagon and GLP-1 were set as cytoplasmic 
stains.
Hormone secretion and assay. Islet GLP-1 and CCK secretion were previously described4. Briefly, 
islets were incubated at a density of 1 islet per 10 µl of media. For GLP-1 secretion studies, the DPP4 inhibi-
tor (Millipore) was added to the media to prevent GLP-1 degradation54. A membrane permeable cAMP analog 
(8-CPT-cAMP, referred to as cAMP) was used to stimulate CCK secretion as previously described4. After incuba-
tion, media was collected, centrifuged at 1000 rpm for 5 min at 4 °C and supernatant stored at −80 °C until further 
analysis. GSIS was carried out as described previously52. Briefly, 45–60 islets were pre-incubated for 30 minutes 
in 0.5 mM glucose at 37 °C. Batches of 5 islets were then incubated for 1 hour at 37 °C in 24-well plates with 
different glucose concentrations and chemical compounds such as, exendin-(9–39) (Ex9) (Tocris Bioscience, 
#2081), proglumide (Tocris Bioscience, #1478), sulfated CCK-8 peptide (Cayman Chemical, #23371), and sul-
fated (pGlu-Gln)-CCK-8 (American Peptide). More details about glucose concentrations and compounds uti-
lized can be found in each figure legend.
GLP-1 was measured using an Active GLP-1 ELISA (Millipore, #EGLP-35K). This ELISA does not detect any 
other forms of GLP-1, GLP-2, or glucagon (manufacturer’s product information). Sulfated CCK levels were meas-
ured by radioimmunoassay with no cross-reactivity to the highly similar gastrin peptides (Alpco Diagnostics, 
now discontinued) as described22. Insulin was measured using an in-house insulin ELISA55, and QuantiFluor® 
dsDNA System (Promega, #E2670) was used to measure islet DNA.
Live-cell imaging. Lean mouse islets were dispersed into small cell clusters using trypsin and gentle pipet-
ting. Clusters were plated onto 35 mm culture dishes with cover glass bottom (Word Precision Instruments, 
#FD35) and cultured at 37 °C in the presence of 5% CO2 with RPMI 1640 medium containing 8 mM glucose, 
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supplemented with 10% fetal bovine serum (FBS) and 1% P/S. For measurements of cytosolic Ca2+, cell clusters 
were pre-incubated with 2.5 μM FuraRed (Molecular Probes, #F3020) in RPMI media for 45 min at 37 °C. At the 
end of the pre-incubation, the cells were washed and placed into a bicarbonate-buffered Krebs solution contain-
ing 120 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 24 mM NaHCO3, 1 g/l BSA, 10 mM HEPES, and 
8 mM glucose. Fluorescence imaging of cytosolic Ca2+ was carried out as previously described38 except for the 
40X/1.30 Oil S Fluor objective (Nikon Instruments). The excitation (ET430/20x and ET500/20x, ET type, Chroma 
Technology Corporation) and emission (650/60 m) filters (BrightLine type, Semrock) were used in combination 
with an FF444/521/608-Di01 dichroic beamsplitter (Semrock) and reported as an excitation ratio (R430/500).
Statistical analysis. Results are presented as mean ± standard error of the mean (SEM). Unless otherwise 
stated, statistical significance was determined by two-way ANOVA and Bonferroni’s post-hoc test, as appropriate, 
using GraphPad Prism 8. Differences were considered significant when P ≤ 0.05.
Data availability
Materials, data, and associated protocols will be made available upon request.
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